|
|
High TRAIL-R2 expression decrease breast cancer survival
Jul 23, 2005, 03:52, Reviewed by: Dr.
|
|
"A number of TRAIL receptor targeting therapies are currently in clinical development. As with other targeted therapies, it is important to determine which patients are more likely to respond to these therapies,"
|
By Yale University,
High expression of TRAIL-R2, a cell surface receptor that triggers cell death, has been shown to be associated with a decrease the survival rates of breast cancer patients according to a study published by Yale Cancer Center researchers in Clinical Cancer Research.
Analyzing 20-year follow-up data from breast cancer patients, using an automated quantitative analysis system (AQUATM) to review tissue microarray specimens, the researchers identified increased intensity of TRAIL receptor expression. AQUATM scores were correlated with clinical and pathologic variables. In addition, TRAIL-R1 and TRAIL-R2 expression were both studied on 95 unmatched normal breast specimens.
Yale Researchers concluded that while TRAIL-R1 expression was not associated with survival, high TRAIL-R2 expression strongly correlated with decreased survival.
"A number of TRAIL receptor targeting therapies are currently in clinical development. As with other targeted therapies, it is important to determine which patients are more likely to respond to these therapies," said Harriet Kluger, MD, author on the study and Assistant Professor of Medicine in the Section of Medical Oncology at Yale School of Medicine. "AQUATM allows us to stratify patients based on expression levels of drug targets in an automated, unbiased fashion. This will help us reach our ultimate goal of practicing personalized medicine, by treating patients based on characteristics of individual tumors,"
The AQUATM system measures and localizes specific variations in protein expression within tissue automatically, with a high level of precision. The multi-tissue proteomic analysis system combines fluorescence-based imaging with automated microscopy and high-throughput tissue microarray technologies. HistoRx has exclusively licensed the AQUATM technology that was developed by David Rimm, M.D., Ph.D. and Robert Camp, M.D., of the Yale University School of Medicine and Yale Cancer Center. 
- Clinical Cancer Research 2005;11(14) July 15, 2005
www.yale.edu
Co-authors of the study include Mary M. McCarthy, and Mario Sznol, and Kyle A. DiVito, Robert L. Camp, and David L. Rimm.
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
Top of Page
|
|
|
|
